BioNTech (NasdaqGS:BNTX) is back in focus after Arbutus Biopharma and Genevant expanded their patent enforcement campaign by filing new lawsuits in Japan and updating an existing Canadian case tied to mRNA lipid nanoparticle technology. Investors have watched BioNTech give back ground over 2026, with the share price down 12.05% year to date and the 1 year total shareholder return declining 18.14%. This suggests momentum has been fading even as fresh earnings, updated guidance and buybacks...
Moderna, led by CEO Stéphane Bancel, is forging the future of mRNA with its new personalized cancer vaccine.
BioNTech has multiple catalysts that could generate a rally of 35% for the stock.
Five years after their pandemic-era success, BioNTech and Moderna are racing to transform promising medical breakthroughs into sustainable businesses.
Delivered the first global data for any PD-(L)1xVEGF bispecific immunomodulator candidate in combination with an investigational antibody-drug conjugate in lung cancer, with pumitamig plus elfetabart drozuntecanAdvanced the first global Phase 3 clinical trial to evaluate pumitamig in combination with Gilead’s TROP2-directed antibody-drug conjugate sacituzumab govitecan in triple-negative breast cancer, pending regulatory approval Presented data demonstrating gotistobart nearly doubled median ove
BioNTech stock drops over 5% as BNT113 mRNA cancer trial misses PFS endpoint. Focus shifts to overall survival in HPV16+ HNSCC study.
Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.